TY - JOUR
T1 - Allergen immunotherapy for allergic asthma
T2 - Protocol for a systematic review
AU - Dhami, Sangeeta
AU - Nurmatov, Ulugbek
AU - Agache, Ioana
AU - Lau, Susanne
AU - Muraro, Antonella
AU - Jutel, Marek
AU - Roberts, Graham
AU - Akdis, Cezmi
AU - Bonini, Matteo
AU - Calderon, Moises
AU - Casale, Thomas
AU - Cavkaytar, Ozlem
AU - Cox, Linda
AU - Demoly, Pascal
AU - Flood, Breda
AU - Hamelmann, Eckard
AU - Izuhara, Kenji
AU - Kalayci, Ömer
AU - Kleine-Tebbe, Jörg
AU - Nieto, Antonio
AU - Papadopoulos, Nikolaos
AU - Pfaar, Oliver
AU - Rosenwasser, Lanny
AU - Ryan, Dermot
AU - Schmidt-Weber, Carsten
AU - Szefler, Stan
AU - Wahn, Ulrich
AU - Van Wijk, Roy Gerth
AU - Wilkinson, Jamie
AU - Sheikh, Aziz
N1 - Publisher Copyright:
© 2016 Dhami et al.
PY - 2016/2/9
Y1 - 2016/2/9
N2 - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for Allergic Asthma. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic asthma. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised. Discussion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
AB - Background: The European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for Allergic Asthma. We seek to critically assess the effectiveness, cost-effectiveness and safety of AIT in the management of allergic asthma. Methods: We will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesised. Discussion: The findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
KW - Allergen immunotherapy
KW - Allergic asthma
KW - Allergy
KW - Disease-modifying
KW - Respiratory allergy
UR - http://www.scopus.com/inward/record.url?scp=85006269845&partnerID=8YFLogxK
U2 - 10.1186/s13601-016-0094-y
DO - 10.1186/s13601-016-0094-y
M3 - Article
AN - SCOPUS:85006269845
SN - 2045-7022
VL - 6
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
IS - 1
M1 - 5
ER -